Biocon Limited board approves QIP at ₹387.74 per share, with issue opening on 12 January 2026 and new oncology biosimilars announced.

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...

Pharma stocks rise as Cipla faces supply issues, Zydus gains FDA approval, and Biocon secures funding through a QIP.

PITTSBURGH, Dec. 6, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has entered into definitive agreements with Biocon Limited ("Biocon") for the sale of Viatris' equity stake ...

Biocon has completed the acquisition of the remaining equity shares of its unlisted subsidiary Biocon Biologics from Mylan ...

On Wednesday, Biocon stock slipped 0.55 per cent to settle at Rs 364.55 apiece on the BSE.

Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process.

Bengaluru: Biocon Limited has successfully concluded a Rs 4,150 crore (approximately USD 460 million) equity fundraise ...

Biocon said the proceeds would be primarily used to meet the cash consideration payable to Mylan Inc, now Viatris, for the ...

PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ — Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug ...